Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins and Reed Abelson

in

Clinical Trials, CVS Caremark Corporation, Drugs (Pharmaceuticals), Eli Lilly and Company, GLP-1 RAs (Drug), Health Insurance and Managed Care, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Research
←Transportation Secretary Gets Pressed Over Repeated Airport Failures And Musk’s FAA Cuts
Johnny Rodriguez, Country Music Star, Dead at 73→

More posts

  • Fiona Cauley & Inevitable Foundation Are Making The Disabled Community “The Main Character” In New Digital Series ‘Talking Sh*t’

  • Lexington Film Office Launches Workforce Development Initiative With Location Managers Guild

  • European grocery chains’ freezers, refrigerators targeted in apparent cyberattacks

  • Newsom proposes $1 billion cap for film and TV tax incentive

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube